Q4 2025 Travere Therapeutics Inc Earnings Call Transcript
Key Points
- Travere Therapeutics Inc (TVTX) achieved record demand and strong revenue growth in the fourth quarter of 2025, driven by increased physician confidence and real-world experience with their products.
- The company reported significant year-over-year growth in revenue, with net product sales reaching $410.5 million for the full year of 2025.
- Travere Therapeutics Inc (TVTX) is advancing its pipeline with the potential approval of Filspari for FSGS, which could become the first FDA-approved medication for this condition.
- The company has resumed site activation for the pivotal phase 3 Harmony study for Pegtobatinase, which could become the first disease-modifying therapy for classical homocystinuria.
- Travere Therapeutics Inc (TVTX) maintains a strong financial position with cash equivalents and marketable securities totaling approximately $322.8 million as of December 31, 2025.
- The FDA's major amendment to the SNDA for Filspari has shifted the target action date to April 13, 2026, indicating potential delays in approval.
- Operating expenses increased, with research and development expenses reaching $57.9 million and general and administrative expenses rising to $101.7 million in the fourth quarter of 2025.
- The company anticipates modestly higher gross-to-net discounts in 2026, which could impact net revenue.
- Travere Therapeutics Inc (TVTX) faces competition from new therapies entering the market, which could affect their market share and growth potential.
- There is uncertainty regarding the FDA's receptivity to proteinuria as an endpoint for FSGS, which could impact the approval process for Filspari.
Good afternoon and welcome to the Trevere Therapeutic fourth-quarter and full-year 2025 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nehra, SVP, Corporate Communications and Investor Relations. Please go ahead, Nivi.
Thank you, operator. Good afternoon and welcome to Trevere Therapeutics' fourth-quarter and full-year 2025 financial results and corporate update call. Thank you all for joining. Today's call will be led by Doctor Eric Dube, our President and Chief Executive Officer. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Commercial Officer; and Chris Cline, our Chief Financial Officer; Dr. Will Rote, our Chief Research Officer will join us for the Q&A.
Before we began, I'd like to remind everyone that statements made during this call regarding matters that are not historical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
